High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

Schizophrenia Research

Volumn 102, Issue 1-3, 2008, Pages 88-95

  Dyer, Michael A ^a   Freudenreich, Oliver ^a   Culhane, Melissa A ^a   Pachas, Gladys N ^a   Deckersbach, Thilo ^a   Murphy, Erin ^a   Goff, Donald C ^a   Evins, A Eden ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acetylcholine; Attention; Galantamine; Nicotine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GALANTAMINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; MUSCLE CRAMP; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TASK PERFORMANCE; TREATMENT OUTCOME; WORKING MEMORY;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; ATTENTION; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GALANTAMINE; HUMANS; INHIBITION (PSYCHOLOGY); MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLACEBOS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; TREATMENT OUTCOME;

EID: 46249116680     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.12.491     Document Type: Article

References (57)

1. Adler L.E., Hoffer L.D., Wiser A., and Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry 150 12 (1993) 1856-1861
2. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., and Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 32 (1992) 607-616
3. Allen T.B., and McEvoy J.P. Galantamine for treatment-resistant schizophrenia. Am. J. Psychiatry 159 7 (2002) 1244-1245
4. Avila M.T., Sherr J.D., Hong E., Myers C.S., and Thaker G.K. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 28 12 (2003) 2184-2191
5. Barr, R.S., Culhane, M.A., Jubelt, L.E., Mufti, R.S., Dyer, M.A., Weiss, A.P., Deckersbach, T., Kelly, J.F., Freudenreich, O., Goff, D.C., Evins, A.E., in press. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (In press; advanced online publication available 04/17/07).
6. Bora E., Veznedaroglu B., and Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin. Neuropharmacol. 28 3 (2005) 139-141
7. Breese C.R., Lee M.J., Adams C.E., Sullivan B., Logel J., Gillen K.M., Marks M.J., Collins A.C., and Leonard S. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23 4 (2000) 351-364
8. Buchanan R.W., Summerfelt A., Tek C., and Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr. Res. 59 1 (2003) 29-33
9. Carlsson M., and Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. TINS 13 (1990) 272-276
10. Cornblatt B.A., Lenzenweger M.F., and Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res. 29 1 (1989) 65-85
11. Csernansky J.G., Martin M., Shah R., Bertchume A., Colvin J., and Dong H. Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology 30 12 (2005) 2135-2143
12. Dalack G.W., Healy D.J., and Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am. J. Psychiatry 155 11 (1998) 1490-1501
13. de Leon J., and Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 76 2-3 (2005) 135-157
14. De Luca V., Wong A.H., Muller D.J., Wong G.W., Tyndale R.F., and Kennedy J.L. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 29 8 (2004) 1522-1526
15. Deutsch S.I., Rosse R.B., Billingslea E.N., Bellack A.S., and Mastropaolo J. Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent. Life Sci. 73 18 (2003) 2355-2361
16. Durany N., Zochling R., Boissl K.W., Paulus W., Ransmayr G., Tatschner T., Danielczyk W., Jellinger K., Deckert J., and Riederer P. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci. Lett. 287 2 (2000) 109-112
17. Fagerlund B., Soholm B., Fink-Jensen A., Lublin H., and Glenthoj B.Y. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 30 1 (2007) 3-12
18. Freedman R., Hall M., Adler L.E., and Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 38 1 (1995) 22-33
19. Freudenreich O., Herz L., Deckersbach T., Evins A.E., Henderson D.C., Cather C., and Goff D.C. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl.) 181 2 (2005) 358-363
20. Harris J.G., Kongs S., Allensworth D., Martin L., Tregellas J., Sullivan B., Zerbe G., and Freedman R. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29 7 (2004) 1378-1385
21. Hohnadel E., Bouchard K., and Terry Jr. A.V. Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52 2 (2007) 542-551
22. Howard A.K., Thornton A.E., Altman S., and Honer W.G. Donepezil for memory dysfunction in schizophrenia. J. Psychopharmacol. 16 3 (2002) 267-270
23. Ishimaru M., Kurumaji A., and Toro M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry 35 (1994) 84-95
24. Jacobsen L.K., D'Souza D.C., Mencl W.E., Pugh K.R., Skudlarski P., and Krystal J.H. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol. Psychiatry 55 8 (2004) 850-858
25. Javitt D., and Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
26. Keefe, R., Malhotra, A., Meltzer, H., Kane, J., Buchanan, R., Murthy, A., Sovel, M., Li, C., Goldman, R., in press. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (In press; advanced online publication available 07/11/07).
27. Kiba H., and Jayaraman A. Nicotine induced c-fos expression in the striatum is mediated mostly by dopamine D1 receptor and is dependent on NMDA stimulation. Brain Res. Mol. Brain Res. 23 1-2 (1994) 1-13
28. Kim J.S., Kornhuber H.H., Schmid-Burgk W., and Holzmuller B. Low cerebrospinal glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20 (1980) 379-382
29. Kumari V., and Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci. Biobehav. Rev. 29 6 (2005) 1021-1034
30. Lee B.J., Lee J.G., and Kim Y.H. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J. Psychopharmacol. 21 4 (2007) 421-427
31. Lee S.W., Lee J.G., Lee B.J., and Kim Y.H. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int. Clin. Psychopharmacol. 22 2 (2007) 63-68
32. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., Drebing C., Berger R., Venn D., Sirota P., Zerbe G., Olincy A., Ross R.G., Adler L.E., and Freedman R. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatry 59 12 (2002) 1085-1096
33. Lindenmayer J.P., Bernstein-Hyman R., and Grochowski S. A new five factor model of schizophrenia. Psychiatr. Q. 65 4 (1994) 299-322
34. Maelicke A., and Albuquerque E.X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur. J. Pharmacol. 393 1-3 (2000) 165-170
35. Mansvelder H.D., and McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 27 2 (2000) 349-357
36. Nomikos G.G., Schilstrom B., Hildebrand B.E., Panagis G., Grenhoff J., and Svensson T.H. Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res. 113 1-2 (2000) 97-103
37. Olincy A., Johnson L.L., and Ross R.G. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res. 117 3 (2003) 223-236
38. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 12 (1995) 998-1007
39. Popa R.V., Pereira E.F., Lopes C., Maelicke A., and Albuquerque E.X. The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease. J. Mol. Neurosci. 30 1-2 (2006) 227-232
40. Puopolo P.R., Pothier M.E., Volpicelli S.A., and Flood J.G. Single procedure for detection, confirmation, and quantification of benzodiazepines in serum by liquid chromatography with photodiode-array detection. Clin. Chem. 37 5 (1991) 701-706
41. Raskind M.A., Peskind E.R., Wessel T., and Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54 12 (2000) 2261-2268
42. Risch S.C., Horner M.D., McGurk S.R., Palecko S., Markowitz J.S., Nahas Z., and DeVane C.L. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophr. Res. 93 1-3 (2007) 131-135
43. Risch S.C., McGurk S., Horner M.D., Nahas Z., Owens S.D., Molloy M., Gilliard C., Christie S., Markowitz J.S., DeVane C.L., Mintzer J., and George M.S. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase 7 2 (2001) 105-110
44. Rosse R.B., and Deutsch S.I. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin. Neuropharmacol. 25 5 (2002) 272-275
45. Samochocki M., Hoffle A., Fehrenbacher A., Jostock R., Ludwig J., Christner C., Radina M., Zerlin M., Ullmer C., Pereira E.F., Lubbert H., Albuquerque E.X., and Maelicke A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 305 3 (2003) 1024-1036
46. Samochocki M., Zerlin M., Jostock R., Groot Kormelink P.J., Luyten W.H., Albuquerque E.X., and Maelicke A. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol. Scand. Suppl. 176 (2000) 68-73
47. Schilstrom B., Ivanov V.B., Wiker C., and Svensson T.H. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32 1 (2007) 43-53
48. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., and Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49 1 (1996) 1-6
49. Schubert M.H., Young K.A., and Hicks P.B. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol. Psychiatry 60 6 (2006) 530-533
50. Smith R.C., Singh A., Infante M., Khandat A., and Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27 3 (2002) 479-497
51. Stryjer R., Strous R., Bar F., Shaked G., Shiloh R., Rozencwaig S., Grupper D., Buchman N., Kotler M., Rabey J.M., and Weizman A. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Hum. Psychopharmacol. 19 5 (2004) 343-346
52. Sziraki I., Sershen H., Benuck M., Hashim A., and Lajtha A. Receptor systems participating in nicotine-specific effects. Neurochem. Int. 33 5 (1998) 445-457
53. Tugal O., Yazici K.M., Anil Yagcioglu A.E., and Gogus A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacology 7 2 (2004) 117-123
54. Wang D., Noda Y., Zhou Y., Mouri A., Mizoguchi H., Nitta A., Chen W., and Nabeshima T. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32 6 (2007) 1261-1271
55. Wang D., Noda Y., Zhou Y., Nitta A., Furukawa H., and Nabeshima T. Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model. Neuropharmacology 52 4 (2007) 1179-1187
56. Wechsler D. Wechsler Adult Intelligence Scale Third Edition (WAIS-III) (1997), Psychological Corporation, San Antonio
57. Weiss A., Jubelt L., Barr R., Goff D., Rigotti N., and Evins A. The effect of transdermal nicotine on episodic memory performance in nonsmoking patients with schizophrenia. Neuropsychopharmacology 31 (2006) S112-S113